AIBioTech has acquired ImmunoTox Inc., a contract research company that provides immunotoxicology and immunopharmacology studies for the pharma, biopharma, and manufacturing sectors. The acquisition expands AIBioTech’s biotechnology services for examining the effects of drugs, chemicals, biologics, and other physical agents on the immune system. ImmunoTox will operate as a division of AIBioTech.   Founder and chief executive officer of ImmunoTox, Inc., Kimber White, Ph.D. said, “We are looking ...